"$35 Insulin Cap Launches, Expanding Affordable Access Nationwide"
Sanofi, a leading insulin manufacturer, has capped the monthly price of its widely prescribed insulin, Lantus, at $35 for insured patients in the U.S. This move follows similar price reductions by other major insulin producers and comes after increased pressure from the government and public, partly due to the Inflation Reduction Act's $35 cap for Medicare users. The change is significant for the 8.5 million Americans dependent on insulin, with up to 25% previously unable to afford their medication. Sanofi also offers a savings program for uninsured patients.